Summary
- CRISPR is the revolutionary method of genes editing that can potentially treat a vast number of genetic diseases.
- The company is also brewing its own line of promising CAR-Ts.
- The partnership with Vertex to access its extensive resources. Fifty percent ownership of Casebia Therapeutics with Bayer to broaden the firm’s pipeline.
- Abundant cash to fund development for the next two years.
- This is the exclusive article for subscribers that we decided to publish earlier this week.
Since Oct. 28, 2016, shares of Crispr Therapeutics (NASDAQ:CRSP), a bioscience firm, focusing on the development and commercialization of gene editing and CAR-T to treat cancers and genetic diseases increased by $5.61 to trade at $19.48 for (over 40% profits). Of note, the recent FDA approval of the two CAR-T products - tisagenlecleucel (Kymriah) of Novartis (NYSE:NVS) for the treatment of refractory acute lymphoblastic leukemia, and axicabtagene ciloleucel (Yescarta) of Gilead (NASDAQ:GILD) for resistant non-Hodgkin lymphomas - opened doors to similar therapeutics. With such exciting developments, Crispr’s share price would have been trading at much higher valuation without the patent litigation issue. In this report, we’ll explicate the company’s stellar technology (gene editing and CAR-T) while going over the patent concern, the robust financials as well as the superb management.
Author’s Notes: The full Integrated BioSci Research is available to subscribers of our marketplace service, Integrated BioSci Investing(where we also deliver in-depth consulting and key market-moving catalyst events).
